RxDoctor Payments Data

Joseph Lutes

Family · Neosho, MONPI 1346512696

Payments from drug & device makers

$866in general payments, 2019–2025

Across 44 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$165
  • Otsuka America Pharmaceutical, Inc.$127
  • E.r. Squibb & Sons, L.L.C.$111
  • EMD Serono, Inc.$96
  • Exact Sciences$47
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$866100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$866 in reported general payments places this provider in the 65th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$722
Medicare patients
20
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$70,357
JanuviaSitagliptin Phosphate38$44,496
JanumetSitagliptin Phos/Metformin Hcl24$31,432
Janumet XrSitagliptin Phos/Metformin Hcl26$25,727
EliquisApixaban30$22,846
Spiriva HandihalerTiotropium Bromide24$17,779
FarxigaDapagliflozin Propanediol18$16,528
LinzessLinaclotide18$14,405
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,410
SymbicortBudesonide/Formoterol Fumarate19$7,051
Incruse ElliptaUmeclidinium Bromide11$4,005
Albuterol Sulfate HfaAlbuterol Sulfate123$3,378
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,271
Atorvastatin Calcium354$1,950
Gabapentin124$1,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$13$23,57937 claims
AbbVieLinzess$240$14,40518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,812 family providers in Missouri.

Other family in Neosho

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →